Itvisma contains the active ingredient in Zolgensma approved in 2019 for children younger than 2 years but is reformulated for intrathecal administration across age groups.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-oks-new-formulation-sma-gene-therapy-itvisma-2025a1000wyv?src=rss
Author :
Publish date : 2025-11-25 16:41:00
Copyright for syndicated content belongs to the linked Source.
